Follow the Money (4.23.2026) Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week. https://t.co/nEWINTOw6L https://t.co/a4oZxqwYhv

True or False: The DESIR axSpA cohort study found a significant association between NSAID use and incident hypertension over 10 years. See if you got it right in the latest RheumIQ quiz at https://t.co/N5rfozh757. https://t.co/tkj0na3bkh

The impact oif obesity on the immune system. Through methylation, obesity imprints memory to CD4+ (helper) T cells, which can last for many years, and promotes immune system dysregulation and inflammation. @emboreports https://t.co/j2tASpZlE0 https://t.co/5CgUrsFZru

APR: Difficult to Treat RA Companion slide deck for the Advanced Practice Rheum: Difficult to Treat Rheumatoid Arthritis video, featuring Dr. Jack Cush. https://t.co/GXnTicNTL6 https://t.co/ojOsMZ4sA7

Are uveitis and psoriasis independently associated with greater spinal radiographic progression in ankylosing spondylitis? Test your knowledge in the latest RheumIQ quiz at https://t.co/N5rfozh757 https://t.co/PjY1iuLv0X

Danish registry study of truncal (2,260) vs superselective (3,810) vagotomy (1977-95) vs general popul. (10:1). Truncal incr. RA risk (aHR 2.62), but selective did not (aHR 1.05. Neither had effect on OA risk https://t.co/dqejtN9TwY https://t.co/R0OJZTxd5T 

Sun Pharma buys out Organon w/ $11.75 billion buyout. Both generated $6.2 billion in 2025 sales. Organon spun off from ‌Merck in 2021, specializes in women’s health and is top 7 in biosimilars. Sun is into dermatology, ophthalmology and oncology-dermatology. https://t.co/zb4hucTqCJ

Presented at AACE Annual Meeting, FREEDOM Real-World Study looked atypical femoral Fxs & found a low AFF risk - 24 AFFs w/ denosumab (0.89/1KPY) vs 397 AFFs w/ bisphosphonates (0.82/1KPY) but no active comparators & excluded pts w/ comorbidities. https://t.co/vRwkfHSXxh https://t.co/xzgC0D5ZTu

TRACE study of 90 axSpA pts Rx w/ either TNFi or secukinumab (150 or 300 mg)- at wk 56, 59% achieved clinical-remission & 43% achieved w56-MRI-remission (SPARCC) w/ benefits by wk 4. Predictors of clinical remission: ASDAS & BMI (@wk16); none @wk56 https://t.co/CEsAeRMvUE https://t.co/SfSAm3u4IM

Twofold Mortality in SLE Despite declining incidence of lupus, mortality for SLE was twice that of controls in this large incident cohort study. https://t.co/Sv7XMnLT3J https://t.co/CURPZ5cYgt

Obesity is more than comorbidity—it’s a driver of inflammation. At #RheumNowLive 2026, Dr. Uzma Haque breaks down weight management strategies that actually move the needle in rheumatology care. 🎧 Listen here: https://t.co/A6fbPvV2tD #Rheumatology #Inflammation #Obesity https://t.co/RLxV44SrUB